XBiotech lance l'offre publique pour le rachat de ses parts à hauteur de 80 millions de dollars
May 17, 2023 23:32 ET
|
XBiotech Inc.
AUSTIN, Texas, 18 mai 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) (« XBiotech ») a annoncé aujourd'hui le commencement de son offre émettrice publique de rachat « à la hollandaise...
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
May 17, 2023 09:00 ET
|
XBiotech Inc.
AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Xbiotech Inc. (NASDAQ: XBIT) (“Xbiotech”) announced today that it commenced a “modified Dutch auction” issuer tender offer to purchase up to...
RADDOG™, the Robot Dog from AITX’s Subsidiary, Robotic Assistance Devices, to Appear on New FOX Reality Series ‘Stars on Mars’
May 15, 2023 08:40 ET
|
Artificial Intelligence Technology Solutions, Inc.
Detroit, Michigan, May 15, 2023 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc., (the “Company”) (OTCPK:AITX), a global leader in AI-driven security and productivity solutions...
XBiotech meldet Rekrutierung des ersten Teilnehmers in klinischer Phase-I-Studie zu Hutrukin, einem neuartigen Therapiekandidaten bei Schlaganfällen
April 17, 2023 10:58 ET
|
XBiotech Inc.
Austin, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc.(NASDAQ: XBIT) hat den ersten Teilnehmer in eine randomisierte, offene, placebokontrollierte klinische Dosiseskalationsstudie...
XBiotech annonce le recrutement du premier sujet dans son essai clinique de phase I pour Hutrukin, un nouveau traitement candidat pour l'AVC
April 17, 2023 10:58 ET
|
XBiotech Inc.
AUSTIN, Texas, 17 avr. 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) a recruté le premier sujet d'une étude clinique ouverte, randomisée et contrôlée par placebo avec escalade des doses,...
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
April 17, 2023 09:00 ET
|
XBiotech Inc.
AUSTIN, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to...
Data Analytics Outsourcing Market is estimated to be US$ 19.35 billion by 2030 with a CAGR of 22.1% during the forecast period – BY PMI
April 05, 2023 19:05 ET
|
PMI
Covina, April 05, 2023 (GLOBE NEWSWIRE) -- “According to the latest research study, the demand of Data Analytics Outsourcing Market accounted for US$ 2.6 billion in 2020 and is estimated to be US$...
ÜberStrategist, a Leading Interactive Entertainment and Tech PR and Marketing Agency, Debuts on the Prestigious 2022 Inc. 5000 Annual List
August 16, 2022 07:00 ET
|
UberStrategist
MORRISVILLE, N.C. , Aug. 16, 2022 (GLOBE NEWSWIRE) -- ÜberStrategist, a leading North American public relations and full-service marketing agency focused on global video game, entertainment, and...
AITX's Subsidiary Robotic Assistance Devices Announces ‘Bailey’s Gift’ Campaign Donating Firearm Detection Devices to Schools
July 19, 2022 08:40 ET
|
Artificial Intelligence Technology Solutions, Inc.
Detroit, Michigan, July 19, 2022 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc., (OTCPK:AITX), along with its wholly owned subsidiary Robotic Assistance Devices, Inc. (RAD)...
XBiotech annonce l'achèvement réussi de la Phase I de l'étude sur le cancer du pancréas
June 20, 2022 15:21 ET
|
XBiotech Inc.
AUSTIN, Texas, 20 juin 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd'hui avoir achevé avec succès la Phase I de son étude 1-BETTER, une étude clinique randomisée, en...